Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry
Authors:
- Adrian WlodarczakAWAdrian Wlodarczak
- Piero MontorsiPMPiero Montorsi
- Johan BennettJBJohan Bennett
- Jan TorzewskiJTJan Torzewski
- Michael HaudeMHMichael Haude
- Mathias VrolixMVMathias Vrolix
- Thomas BuckTBThomas Buck
- Adel AminianAAAdel Aminian
- Rene J. van der SchaafRSRene J. van der Schaaf
- Amin Arrif NuruddinANAmin Arrif Nuruddin
- Michael K.Y. LeeMLMichael K.Y. Lee
- 1 February 2020
- journal article
- editorial
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 15 (15) , e1383-e1386
Abstract
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Keywords
This publication has 4 references indexed in Scilit:
- Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12‐month outcomes of BIOSOLVE‐II and BIOSOLVE‐IIICatheterization and Cardiovascular Interventions, 2018
- Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-IIIEuroIntervention, 2017
- Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016EuroIntervention, 2016
- Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summaryEuropean Heart Journal, 2015